An update on potential therapeutic strategies for Parkinson’s disease based on pathogenic mechanisms

References

• Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson’s disease. Move Disord Off J Move Disord Soc. 2013;28(1):24–30.
   PubMed Web of Science ®Google Scholar
• Bras J, Guerreiro R, Hardy J. SnapShot: genetics of Parkinson’s disease. Cell. 2015;160(3):570–570, e571.
   PubMed Web of Science ®Google Scholar
• Chai C, Lim KL. Genetic insights into sporadic Parkinson’s disease pathogenesis. Curr Genomics. 2013;14(8):486–501.
   PubMed Web of Science ®Google Scholar
• Mullin S, Schapira A. The genetics of Parkinson’s disease. Br Med Bull. 2015;114(1):39–52.
   PubMed Web of Science ®Google Scholar
• Moree B, Yin G, Lazaro DF, et al. Small molecules detected by second-harmonic generation modulate the conformation of monomeric alpha-synuclein and reduce its aggregation in cells. J Biol Chem. 2015;290(46):27582–27593.
   PubMed Web of Science ®Google Scholar
• Toth G, Gardai SJ, Zago W, et al. Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson’s disease. PLoS One. 2014;9(2):e87133.
   Web of Science ®Google Scholar
• Lorenzen N, Nielsen SB, Yoshimura Y, et al. How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro. J Biol Chem. 2014;289(31):21299–21310.
   PubMed Web of Science ®Google Scholar
• Levin J, Schmidt F, Boehm C, et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014;127(5):779–780.
   PubMed Web of Science ®Google Scholar
• Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 2013;125(6):795–813.
   PubMed Web of Science ®Google Scholar
• Savolainen MH, Richie CT, Harvey BK, et al. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol Dis. 2014;68:1–15.
   PubMed Web of Science ®Google Scholar
• Myohanen TT, Hannula MJ, Van Elzen R, et al. A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson’s disease. Br J Pharmacol. 2012;166(3):1097–1113.
   PubMed Web of Science ®Google Scholar
• Biswas A, Gupta A, Naiya T, et al. Molecular pathogenesis of Parkinson’s disease: identification of mutations in the Parkin gene in Indian patients. Parkinsonism Relat Disord. 2006;12(7):420–426.
   PubMed Web of Science ®Google Scholar
• Sriram SR, Li X, Ko HS, et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet. 2005;14(17):2571–2586.
   PubMed Web of Science ®Google Scholar
• Jiang H, Jiang Q, Liu W, et al. Parkin suppresses the expression of monoamine oxidases. J Biol Chem. 2006;281(13):8591–8599.
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Hanson I, Andersen JK. Mao-B elevation decreases parkin’s ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Radic Res. 2012;46(8):1011–1018.
   PubMed Web of Science ®Google Scholar
• Kandadai RM, Jabeen SA, Kanikannan MA, et al. Safinamide for the treatment of Parkinson’s disease. Expert Rev Clin Pharmacol. 2014;7(6):747–759.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Rosa MM, Abreu D, et al. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2015;5(6):481–496.
   PubMedGoogle Scholar
• Kouti L, Noroozian M, Akhondzadeh S, et al. Nitric oxide and peroxynitrite serum levels in Parkinson’s disease: correlation of oxidative stress and the severity of the disease. Eur Rev Med Pharmacol Sci. 2013;17(7):964–970.
   PubMed Web of Science ®Google Scholar
• Ozawa K, Komatsubara AT, Nishimura Y, et al. S-nitrosylation regulates mitochondrial quality control via activation of parkin. Sci Rep. 2013;3:2202.
   PubMed Web of Science ®Google Scholar
• Singh S, Das T, Ravindran A, et al. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson’s disease. Redox Rep Commun Free Radical Res. 2005;10(2):103–109.
   Web of Science ®Google Scholar
• Ko HS, Lee Y, Shin JH, et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci USA. 2010;107(38):16691–16696.
   PubMed Web of Science ®Google Scholar
• Godena VK, Brookes-Hocking N, Moller A, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun. 2014;5:5245.
   PubMed Web of Science ®Google Scholar
• Rane P, Shields J, Heffernan M, et al. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology. 2012;62(7):2409–2412.
   PubMed Web of Science ®Google Scholar
• Choong CJ, Sasaki T, Hayakawa H, et al. A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson’s disease. Neurobiol Aging. 2016;37:103–116.
   PubMed Web of Science ®Google Scholar
• Kramer T, Lo Monte F, Goring S, et al. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson’s disease models. Acs Chem Neurosci. 2012;3(3):151–160.
   PubMed Web of Science ®Google Scholar
• Decressac M, Volakakis N, Bjorklund A, et al. NURR1 in Parkinson disease-from pathogenesis to therapeutic potential. Nat Rev Neurol. 2013;9(11):629–636.
   PubMed Web of Science ®Google Scholar
• Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137(1):47–59.
   PubMed Web of Science ®Google Scholar
• Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease. Proc Natl Acad Sci. 2015;112(28):8756–8761.
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Ngoei KRW, Zhao TT, et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Bba-Proteins Proteom. 2010;1804(3):463–475.
   PubMed Web of Science ®Google Scholar
• Chambers JW, Pachori A, Howard S, et al. Small molecule c-Jun-N-terminal Kinase (JNK) inhibitors protect dopaminergic neurons in a model of Parkinson’s disease. Acs Chem Neurosci. 2011;2(4):198–206.
   PubMed Web of Science ®Google Scholar
• Dyson SC, Barker RA. Cell-based therapies for Parkinson’s disease. Expert Rev Neurother. 2011;11(6):831–844.
   PubMed Web of Science ®Google Scholar
• Kefalopoulou Z, Politis M, Piccini P, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014;71(1):83–87.
   PubMed Web of Science ®Google Scholar
• Mendez I, Vinuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med. 2008;14(5):507–509.
   PubMed Web of Science ®Google Scholar
• Marei HE, Lashen S, Farag A, et al. Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson’s disease. J Cell Physiol. 2015;230(7):1614–1629.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang ZJ, Oldenburg M, et al. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells. 2008;26(1):55–63.
   PubMed Web of Science ®Google Scholar
• Daadi MM, Grueter BA, Malenka RC, et al. Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson’s disease. PLoS One. 2012;7(7):e41120.
   Google Scholar
• Hallett PJ, Deleidi M, Astradsson A, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell. 2015;16(3):269–274.
   PubMed Web of Science ®Google Scholar
• Emborg ME, Liu Y, Xi J, et al. Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep. 2013;3(3):646–650.
   PubMed Web of Science ®Google Scholar
• Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res J Lab Clin Med. 2010;155(2):62–70.
   Web of Science ®Google Scholar
• Yan M, Sun M, Zhou Y, et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson’s disease in a rhesus monkey model. PLoS One. 2013;8(5):e64000.
   PubMed Web of Science ®Google Scholar
• Kim J, Su SC, Wang H, et al. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell. 2011;9(5):413–419.
   PubMed Web of Science ®Google Scholar
• Zou Q, Yan Q, Zhong J, et al. Direct conversion of human fibroblasts into neuronal restricted progenitors. J Biol Chem. 2014;289(8):5250–5260.
   PubMed Web of Science ®Google Scholar
• Kim SM, Flasskamp H, Hermann A, et al. Direct conversion of mouse fibroblasts into induced neural stem cells. Nat Protoc. 2014;9(4):871–881.
   PubMed Web of Science ®Google Scholar
• Allen PJ, Feigin A. Gene-based therapies in Parkinson’s disease. Neurother J Am Soc Exp NeuroTher. 2014;11(1):60–67.
   Web of Science ®Google Scholar
• Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369(9579):2097–2105.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309–319.
   PubMed Web of Science ®Google Scholar
• Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980–1983.
   PubMed Web of Science ®Google Scholar
• Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20):1662–1669.
   PubMed Web of Science ®Google Scholar
• Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383(9923):1138–1146.
   PubMed Web of Science ®Google Scholar
• Rodrigues TM, Jeronimo-Santos A, Outeiro TF, et al. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson’s disease. Drugs Aging. 2014;31(4):239–261.
   PubMed Web of Science ®Google Scholar
• Su X, Kells AP, Huang EJ, et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther. 2009;20(12):1627–1640.
   PubMed Web of Science ®Google Scholar
• Kells AP, Eberling J, Su X, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci Off J Soc Neurosci. 2010;30(28):9567–9577.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400–408.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164–1172.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Baumann TL, Bartus RT. Long-term safety of Parkinson’s disease patients receiving AAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther. 2016. doi:10.1089/hum.2015.134. [Epub ahead of print]
   PubMedGoogle Scholar
• Vercammen L, Van der Perren A, Vaudano E, et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson’s disease. Mol Ther. 2006;14(5):716–723.
   PubMed Web of Science ®Google Scholar
• Paterna JC, Leng A, Weber E, et al. and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice FREE (vol 15, pg 698, 2007). Mol Ther. 2007;15(6):1221–1221.
   Web of Science ®Google Scholar
• McCormack AL, Mak SK, Henderson JM, et al. α-Synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One. 2010;5(8):e12122.
   Web of Science ®Google Scholar
• Khodr CE, Sapru MK, Pedapati J, et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons. Brain Res. 2011;1395:94–107.
   PubMed Web of Science ®Google Scholar
• Khodr CE, Becerra A, Han Y, et al. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 2014;1550:47–60.
   PubMed Web of Science ®Google Scholar
• Han Y, Khodr CE, Sapru MK, et al. A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 2011;1386:15–24.
   PubMed Web of Science ®Google Scholar
• Visanji NP, Brooks PL, Hazrati LN, et al. The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol Commun. 2013;1:2.
   PubMedGoogle Scholar
• Recasens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351–362.
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Breydo L, Green R, et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis. 2014;69:76–92.
   PubMed Web of Science ®Google Scholar
• Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014;20(2):130–138.
   PubMed Web of Science ®Google Scholar
• Unterberger U, Lachmann I, Voigtländer T, et al. Detection of disease-associated in α-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol. 2014;33(09):329–334.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Walter GC, Wilder SL, et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience. 2008;153(3):733–750.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• George S, Rey NL, Reichenbach N, et al. Alpha-synuclein: the long distance runner. Brain Pathol. 2013;23(3):350–357.
   PubMed Web of Science ®Google Scholar
• Lamberts JT, Hildebrandt EN, Brundin P. Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson’s disease: a speculative synthesis. Neurobiol Dis. 2015;77:276–283.
   PubMed Web of Science ®Google Scholar
• Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease. Biochim Biophys Acta. 2014;1842(1):7–21.
   PubMed Web of Science ®Google Scholar
• Bu XL, Wang X, Xiang Y, et al. The association between infectious burden and Parkinson’s disease: a case-control study. Parkinsonism Relat Disord. 2015;21(8):877–881.
   PubMed Web of Science ®Google Scholar
• De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious agents and neurodegeneration. Mol Neurobiol. 2012;46(3):614–638.
   PubMed Web of Science ®Google Scholar
• Wu WY, Kang KH, Chen SL, et al. Hepatitis C virus infection: a risk factor for Parkinson’s disease. J Viral Hepat. 2015;22(10):784–791.
   PubMed Web of Science ®Google Scholar
• Ha D, Stone DK, Mosley RL, et al. Immunization strategies for Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S218–221.
   Google Scholar
• Hutter-Saunders JA, Mosley RL, Gendelman HE. Pathways towards an effective immunotherapy for Parkinson’s disease. Expert Rev Neurother. 2011;11(12):1703–1715.
   PubMed Web of Science ®Google Scholar
• Lacan G, Dang H, Middleton B, et al. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J Neurosci Res. 2013;91(10):1292–1302.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang Y, Yang X, et al. Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson’s disease. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2013;34(9):1559–1570.
   Google Scholar
• Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron. 2005;46(6):857–868.
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Mattner F, et al. Affitope (R) - based vaccines: results from phase I support the further clinical development of affitope (R) Ad02. Neurobiol Aging. 2012;33:S30–S31.
   Google Scholar
• Schneeberger A, Mandler M, Otava O, et al. Development of affitope vaccines for Alzheimer’s disease (Ad) – from concept to clinical testing. J Nutr Health Aging. 2009;13(3):264–267.
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Mattner F, et al. AFFITOME(R) technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin. 2010;6(11):948–952.
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Mattner F, et al. Vaccination for Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S11–S13.
   Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Movement Disord. 2015;30(11):1442–1450.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. A retrospective analysis of the Alzheimer’s disease vaccine progress-the critical need for new development strategies. J Neurochem. 2016. doi:10.1111/jnc.13608. [Epub ahead of print]
   PubMedGoogle Scholar
• Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease a systematic review and meta-analysis. Diabetes Care. 2011;34(12):2614–2623.
   PubMed Web of Science ®Google Scholar
• Lu L, Fu DL, Li HQ, et al. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS One. 2014;9(1):e85781.
   Web of Science ®Google Scholar
• Brauer R, Bhaskaran K, Chaturvedi N, et al. Incidence of Parkinson’s disease among people with diabetes: a retrospective cohort study. PLoS Med. 2015;12(7):e1001854.
   Google Scholar
• Wahlqvist ML, Lee MS, Hsu CC, et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18(6):753–758.
   PubMed Web of Science ®Google Scholar
• Ramalingam M, Kim SJ. The neuroprotective role of insulin against MPP-induced Parkinson’s disease in differentiated SH-SY5Y cells. J Cell Biochem. 2015;117(4):917–926.
   PubMed Web of Science ®Google Scholar
• Carta AR, Frau L, Pisanu A, et al. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience. 2011;194:250–261.
   PubMed Web of Science ®Google Scholar
• Shen T, Pu J, Zheng T, et al. Induced neural stem/precursor cells for fundamental studies and potential application in neurodegenerative diseases. Neurosci Bull. 2015;31(5):589–600.
   PubMed Web of Science ®Google Scholar